biostudies-literatureUnknown4(4)Zhu E<h4>Background</h4>IL-13 plays a key role in the induction and perpetuation of type 2 immune responses associated with the development of atopic dermatitis and other chronic inflammatory diseases. mAbs targeting IL-13 have demonstrated efficacy in IL-13-driven diseases; however, current therapeutics require dosing every 2 to 4 weeks, resulting in significant injection burden for patients. APG777 is a humanized, IgG1 IL-13-targeting mAb that has been engineered to have an optimized pharmacokinetic profile, allowing for less frequent dosing.<h4>Objective</h4>We sought to investigate the <i>in vitro</i> potency and <i>in vivo</i> pharmacokinetics of APG777.<h4>Methods</h4>The affinity of APG777 was characterized using surface plasmon resonance; the half-maximal inhibitory concentration (IC<suThe journal of allergy and clinical immunology. Global100545https://www.ebi.ac.uk/biostudies/studies/S-EPMC12419008biostudies-literature&lt;i&gt;In vitro&lt;/i&gt; potency and pharmacokinetics of APG777, a novel anti-IL-13 mAb.PMC12419008Prentice HDabora ROh JShaheen HDambkowski CLZhu EGandhi NAWickman GDillinger Lfalse&lt;i&gt;In vitro&lt;/i&gt; potency and pharmacokinetics of APG777, a novel anti-IL-13 mAb.<h4>Background</h4>IL-13 plays a key role in the induction and perpetuation of type 2 immune responses associated with the development of atopic dermatitis and other chronic inflammatory diseases. mAbs targeting IL-13 have demonstrated efficacy in IL-13-driven diseases; however, current therapeutics require dosing every 2 to 4 weeks, resulting in significant injection burden for patients. APG777 is a humanized, IgG1 IL-13-targeting mAb that has been engineered to have an optimized pharmacokinetic profile, allowing for less frequent dosing.<h4>Objective</h4>We sought to investigate the <i>in vitro</i> potency and <i>in vivo</i> pharmacokinetics of APG777.<h4>Methods</h4>The affinity of APG777 was characterized using surface plasmon resonance; the half-maximal inhibitory concentration (IC<su2025-01-01T00:00:00Z2025 Nov2026-05-26T11:08:24.596Z2026-05-24T03:07:06.316ZS-EPMC124190084093395710.1016/j.jacig.2025.100545